Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06964776) titled 'A Study of LY4268989 (MORF-057) in Healthy Participants' on May 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Healthy
Intervention:
Drug: LY4268989
Drug: Placebo
Drug: Midazolam
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 2025
Target Sample Size: 66
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06964776
Disclaimer: Curated by H...